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ABSTRACT 
Topical drug delivery system is defined as the pharmaceutical dosage form which when applied onto the skin provides protection of skin and 
prevents serious skin disorders. Topical drug are being used for several years and still have its potential in new pharmaceutical technologies 
investigated. Skin is the most easily accessible organ of the body which has the potential to facilitate the delivery of several drugs with better 
efficacy, confining the pharmacological or other effect of the drug to the surface of the skin. Micelles are colloidal particles with a size smaller than 
100 nm that allow a great depth of tissue penetration for targeted drug delivery, but rapidly disintegrate in the body. Microparticles containing 
micelles have the potential for delivering hydrophobic drug encapsulated in micelles on the target site in the specific part of the body. Micellar 
microparticles allow the improvement of solubility and dissolution of poorly soluble drugs. Microparticles containing micelles have the potential for 
delivering micelle-encapsulated hydrophobic drugs in targeted therapy. This article reviews the topical drug delivery system, colloidal drug delivery 
system and aspects and literature reviewed on micellar microparticles and its advantages in pharmaceuticals. An overview of reviews was 
conducted to locate published literature between 2000 and 2017.  
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Topical drug delivery system (TDDS) is defined as the 
pharmaceutical dosage form applied onto the skin directly for the 
treatment of skin disease. These are intended to confine the 
pharmacological effect of the drug onto the surface of the skin [1]. 
The TDDS includes large variety of pharmaceutical dosage form like 
liquid preparations, semisolids and spray powders. However, the 
most widely used semisolid preparation for topical drug delivery 
includes gels, creams and ointments [2]. Topical formulations are 
applied to the superficial areas such as the skin, eyes, nose and 
vagina for the treatment of local diseases [3]. 
Advantages of topical drug delivery 
Topical administration has numerous advantages and can be 
summarised as follows:  
1. Hepatic first-pass metabolism and the GIT metabolism are avoided 
2. Offers an alternative pathway for patients who have oral dosing 
issues, such as in unconscious patients 
3. Cutaneous delivery can provide direct access to the diseased or 
target site such as for fungal skin disease or eczema 
4. Fewer side effects related to systemic toxicity compared to other 
routes of administration  
5. Patient compliance and acceptance 
6. Ease and convenience of application 
7. Painless and non-invasive technique 
8. Improvement in drug bioavailability 
9. Better physiological and pharmacological response 
10. Minimum systemic toxicity and exposure of drug to non-
infectious tissue/sites 
11. Ability to deliver drug more selectively 
12. Enhanced suitability for self-medication [4-6] 
TDDS involve the introduction of a drug to the surface of the body, in 
a formulation which can be absorbed. When the topical formulation 
is applied onto the skin, it should interact with the skin environment, 
which could further influence the rate of release of the compound in 
order to achieve adequate skin absorption [7]. The TDDS are 
generally applied for the purpose as antiseptics, antifungal agents, 
skin emollients and protectants [8]. Skin is the main route of topical 
drug delivery system [9]. Skin is most accessible organ and is 
potential to facilitate the delivery of several drugs with better 
efficacy than rest of any other route of administration [8].  
In TDDS, drug reaches to the site of action via diffusion and their 
absorption takes place on the skin [10]. This route is one of the best 
options for the cutaneous purpose [11]. These systems are often 
very easy for patients to use, which makes them appealing. In all 
cases, the goal of a drug delivery system is to get the right dosage to 
the right place [6]. Many topical preparations, however, contain 
therapeutically active ingredients which is dispersed or dissolved in 
the base. The release rates of topical medications depend solely on 
the physical and chemical, properties of the carrier and the 
medication used [12-14].  
The topical formulations are known for its local dermatological 
action and it should deliver the medication across the localised area 
of the skin. To develop an ideal dosage form one must take into 
account retention of the dosage form, the flux of drug across the skin 
and patient acceptability of the formulation [15-17]. As topical 
formulations contain multiple components with active ingredients it 
should be compatible and should provide stable chemical 
environment for all the ingredients [7].  
The stratum corneum of the skin is very selective as it permits 
selectively due to which the drug transport through skin becomes 
limited. The penetrants that have particular physiochemical 
properties can pass through the skin adequately under passive 
conditions [18, 19].  
A topical dermatological product must be aesthetically pleasing, 
physically and chemically stable and have an adequate shelf life. 
Topical drug delivery system allows optimum penetration of the 
drug into the skin membrane.  
A successful topical formulation must comply with the following 
properties: [20-22] 
1. Physically and chemically stable having an adequate shelf life 
2. Releases drug from the formulation and delivers it into the skin 
as required for the target indication 
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3. Cosmetically elegant and acceptable to patients 
4. Contains only excipients that are necessary, FDA-approved or 
acceptable from a regulatory perspective, and acceptable for the 
disease state 
5. Easy to apply and compatible with the desired packaging 
6. Scalable manufacturing processes on a commercial level [23-26] 
Drug delivery across the skin 
The skin is composed of 3 layers being: epidermis, dermis and 
subcutaneous [27]. The epidermis is the most superficial layer of the 
skin and is composed of stratified keratinized squamous epithelium 
which varies in thickness in different parts of the body [28]. The skin 
being relatively waterproof protects the delicate structure like blood 
vessels and venous plexus that get the blood inflow from the skin 
capillaries underneath the skin [29]. The skin is the directly 
assessable organ for the diagnosis and treatment of various 
disorders. The drug absorption from a topical formulation involves 
three primary mechanisms: transcellular, intercellular, and 
follicular. Most of the drugs pass through the lipid bilayer to viable 
layers of the skin or through pilosebaceous route. The skin acts as a 
two-way barrier for prevention and loss of water and electrolytes. 
The barrier is present in the outermost layer of the epidermis, the 
stratum corneum [30-36]. 
The development of topical drug delivery system requires a 
descriptive knowledge of the therapeutic agents as well as the 
excipients used in the formulation. The selection of excipients 
should be such that it can easily penetrate the skin barrier and the 
drug is delivered to the desired/targeted site [37, 38]. In topical 
formulations, here the micellar microparticles are administered onto 
the skin through cream as a semisolid dosage form. The 
Microparticles entrapped micelles have the potential to deliver 
hydrophobic drug encapsulated within micelles on the targeted site. 
Colloidal drug delivery system 
Colloidal drug delivery systems (CDDS) is the delivery system 
containing particulates of Nanometric range which includes 
niosomes, liposomes, multiple emulsions, nanospheres and 
ceramics. CDDS are essentially required for the transportation of 
loaded drug to the targeted/specific site selectively. Colloids are the 
intermediate kind of solutions whose properties lie between true 
solution and suspension [39]. A colloidal system is a two-phase 
system containing a dispersed phase and a continuous phase. A 
continuous phase is the one in which the very fine particles are 
suspended known as a dispersed phase. The colloidal dispersions 
vary from solutions on the basis of particle size of the dispersed 
phase and its apparent stability. The dispersed phase in the colloidal 
system is uniformly dispersed in the continuous medium and hence 
forming a homogenous solution not visible to naked eyes or even 
with an ordinary microscope. However, the colloidal solution is a 
heterogeneous dispersion of two immiscible phases when under 
ultra-microscope [40]. 
Carriers used in topical drug delivery system 
Colloidal drug carrier is essentially required to transport the loaded 
drug successfully. They are the drug vectors that sequester and retain 
the drug delivery route until it is transported at the targeted site. The 
targeting of the drug at the specific site not only improve the 
therapeutic efficacy but also reduce the amount of drug incorporated 
required for therapeutic response and minimizing unwanted toxic 
effects. The colloidal carriers deliver the drug only to targeted site 
thereby minimize the overall drug consumption and related side 
effects to a greater extent. Micellar solutions, liquid crystal dispersions, 
nanoparticle dispersions, and vesicles are the drug carrier systems 
consist of small particles of 10-400 nm diameters and showed a great 
promise as drug delivery systems. The major goal of developing 
formulations is to obtain a system with optimized drug loading and 
release properties, longer shelf-life and lower toxicity. The colloidal 
carrier should be able to cross the anatomical skin barrier effectively. 
It should be recognized by the target cells specifically and selectively. 
The carriers should be non-toxic, non-immunogenic; the bio modules 
should not be ubiquitous [37, 41]. 
Micellization 
The micelles are the aggregates of surfactant molecule that disperse 
in a liquid colloidal solution [42]. The micelles formation depends 
solely on the concentration of the surfactant in the polar or non-
polar solvents. The process of forming micelles is called as 
Micellization. The surfactant when added at lower concentration 
monomers disperse at the lower surface or aggregate at the 
interface until the entire surface gets saturated by the surfactants. 
On further addition of surfactants, the concentration of monomers in 
the solution increases and it starts forming micelles. This 
concentration at which the micelles formation starts is called as CMC 
(Critical Micelle Concentration). CMC is the concentration of 
monomers at which micelles formation start insolvent at a particular 
temperature. Micelles form only when the concentration of 
surfactant is greater than the CMC [43]. 
Micelles are lipid molecules present in the spherical form in the 
aqueous solutions. These are supramolecular, non-static structures 
formed by surfactant molecules in aqueous solutions [44]. The 
micelles are formed due to the amphipathic nature of the fatty acids 
which means they contain both hydrophobic and hydrophilic group 
[45]. They usually contain a polar or hydrophilic head group onto 
the surface in contact with water. The hydrophobic or non-polar tail 
forms the inner part of the micelles away from the water surface 
[46]. Micelles are thermodynamically stable and easily reproducible, 
but they can be destroyed by water dilution when the surfactant 
concentration is below its CMC [47].  
Types of micelles 
1. Monomeric Micelles 
2. Reverse micelles 
3. Polymeric micelles 
Mechanism of drug transport through skin by colloids 
Skin interaction with the colloids occurs either at the skin surface or 
in the deeper layer of the skin called stratum corneum. Hofland et al., 
demonstrated the process of adsorption and fusion of vesicles onto 
the surface which results in the formation of rough structures on top 
of the outermost corneocytes [48, 49]. The treatment of the skin 
with liquid state liposomes and niosomes results in the changes in 
the stratum corneum. The application of gel state niosomes resulted 
in no ultrastructural changes [50]. The components of liquid state 
liposomes and niosomes can enter the deeper layers of the stratum 
corneum where they can modify the intercellular lipid lamellae, 
whereas the components of gel state niosomes remain on the skin 
surface. The liquid state niosomes and liposomes are effective in 
increasing the drug transport into and across the skin. This is in 
accordance with a study that found a correlation between the skin 
penetration and the fluidity of the vesicle bilayers determined by 
electron spin resonance [51]. It is concluded from the above studies 
that liposomes and niosomes can penetrate into stratum corneum 
[52-54].  
Remarkably, it was noticed that these liposomes are very flexible 
lipid vesicles. An increased structure deformability of the lipid 
bilayers will directly result in skin interactions. The liquid state 
being structurally deformable can enter the stratum corneum 
whereas gel state liposomes and rigid liquid vesicles do not enter the 
stratum corneum as intact entities. There are two major pathway 
from which the encapsulated drug release from the micellar core. 
These pathways involve the dissociation of micelles followed by the 
drug cleavage from the unimer and the drug cleavage within the 
micelle followed by diffusion out of the drug delivery system. There 
are various ways to control the cleavage. For micellar dissociation, 
three mechanisms exist by which the degradation occurs [55]. For 
drug cleavage followed by diffusion, the release depends on the 
chemical conjugation of the drug to the hydrophobic polymer [56]. 
Cloud point technique (CPT) 
The cloud point technique (CPT) is a phenomenon in which an 
aqueous solution of some surfactant becomes turbid and separates 
into two isotropic phases under varied conditions of temperature 
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and pressure or when appropriate substance is added to solution. 
The surfactant solution becomes turbid because it attains the cloud 
point temperature. At this point, the original surfactant solution 
separates into a surfactant phase of small volume, which is rich in 
the surfactant and containing the analyte or metal (organic or 
inorganic species) trapped by micellar structures and a bulk diluted 
aqueous phase [57, 58]. The main advantage of cloud point 
technique is it uses an aqueous solution of the surfactants that are 
inexpensively resulting in lesser cost of reagents. Surfactants are not 
toxic, not volatile, and not easily fl ammable, unlike organic solvents. 
It is a simple, inexpensive, and highly efficient meth od for the 
formation of micelles. 
Micellar microparticles or colloidal microparticles 
Microparticle entrapped micelles is a delivery system in which the 
particles of the micellar range are ensemble for drug and gene 
delivery in specific parts of the body. Microparticles containing 
micelles have the potential for delivering micelle encapsulated 
hydrophobic drug on targeted site [59-63]. Micelles have been used 
as drug carriers for administration and exhibit many advantages 
including their ease of production, long circulation times and having 
surfaces that are readily modified with targeting ligands.  
It was previously shown that various hydrophobic agents could be 
successfully incorporated into micelles [64-66]. The major goals in 
designing colloidal microparticles topical formulation are to 
improve topical dosage forms that deliver the API locally (at site of 
application) in an efficient and effective manner, to tailor drug 
deposition, disposition and permeation kinetics through formulation 
engineering (altered composition, drug loading, droplet size, etc.).  
Micellar delivery systems that are smaller than 100 nm can be 
readily prepared. The micelles can easily penetrate the tissue for 
targeted drug delivery but they disintegrate rapidly leading to faster 
release. The microparticles formation of these micelles can be an 
effective approach to sustain the release of the drug and also provide 
solid structures for further incorporation into a dosage form [67]. 
Advantages of colloidal microparticles 
1. Have potential of delivering drug to targeted site 
2. Allow the encapsulation of the hydrophobic drug 
3. Are easy to produce and are economic 
4. Improve topical dosage forms that deliver the API locally (at site 
of application) in an efficient and effective manner 
5. Tailor drug deposition, disposition and permeation kinetics 
6. Sustain the drug release 
The application of micellar drug delivery system is owing to the 
improvement of bioavailability, minimization of drug degradation, 
prevention of harmful side effects. Micellar systems can solubilize 
poorly soluble drugs and thus increase the bioavailability of those 
drugs. It is recognized that solubilization in aqueous surfactant 
solutions at surfactant concentrations exceeding the critical micelle 
concentration is the means to formulate a variety of slightly soluble 
to practically insoluble compounds in the solution state [68]. 
Micellar solubilization improves the solubility of drugs. Micelle 
entrapped into microparticle is a sensible approach of converting an 
aqueous micellar solution into solid for ease of administration and 
patient compliance. 
Literature reviewed on microparticles entrapped micelles 
It was showed that reverse micelles made of amphiphilic 
phosphazene polymers can enhance the encapsulation efficiency and 
the in vitro release profile of poly (lactide-co-glycolide) (PLGA) 
microparticles. While plain PLGA microparticles released more than 
50% of the drug in 1 d, optimal micelle formulations encapsulating 
PLGA particles released less than 30% of the drug at the end of 60 d. 
Microparticles are enabling the use of micelles as sustained release 
delivery systems. In order to sustain drug delivery beyond 2 mo, for 
instance up to 6 mo or a few years, microparticles and implant 
delivery systems are currently suitable options [69].  
A new platform was developed for the pulmonary delivery of the 
therapeutic photosensitizing drug, hematoporphyrin (Hp) in the 
form of microparticles containing micelles in which the drug was 
encapsulated. Micellar Hp was formulated using different 
poloxamers and one of these, Pluronic L122-Hp, was subsequently 
incorporated into lactose microparticles by spray-drying. Various 
Spectral and morphological analysis was carried out before and after 
the dissolution of the microparticles in the water on both micellar 
Hp, and lactose microparticles containing micellar Hp (lactose-
micellar Hp). The Photodynamic activity of the various Hp samples 
were evaluated in human lung epithelial carcinoma A549 cells using 
a light-emitting diode (LED) device at a wavelength of 630±5 nm. It 
was noted that the spectral properties, as well as the photodynamic 
activity of the micellar Hp, were similar to that of microparticles 
formulated by spray-drying. Microparticles containing micelles have 
the potential for delivering micelle-encapsulated hydrophobic drugs 
in targeted therapy of pulmonary diseases [70]. 
It was reported that MEM technology containing drug entrapped 
micelles can successfully preserve the properties and integrity. 
Valsartan (VAL) was solubilized in cremophor EL micelles at cloud 
point temperature; lactose was dissolved in micellar dispersion and 
the dispersion was directly spray-dried to obtain solid product, 
which was subsequently converted into tablets using suitable 
excipients. Improved dissolution performance of valsartan tablets 
was observed when VAL tablets were produced by applying MEM 
technology. These tablets exhibited superior dissolution rate over 
controls and marketed tablets in all media employed irrespective of 
pH conditions and composition [71]. 
The dissolution rate of naproxen using micellar solubilization 
technology was studied. Cloud point temperature of the non-ionic 
surfactants was used as the technique for the solubility study. Cloud 
point technique is helpful in solubilizing the maximum amount of 
drug into the surfactant at the cloud point temperature. Polysorbate 
80 was used to solubilize naproxen at cloud point temperature to 
form micelles further lactose was dissolved in micellar dispersion 
and the dispersion was directly spray-dried to obtain microparticles. 
These microparticles were converted into tablets using suitable 
excipients. It was found that the dissolution rate was higher in all the 
dissolution media irrespective of the pH conditions in both spray-
dried naproxen particles and directly compressed tablets [72]. 
The formulation of fenofibrate modified by MEM technology (FB-
MEM) was prepared. Fenofibrate was solubilized through CPT in 
various surfactants such as Tween 60, 80, Kolliphor P407, Gelucire 
44/14, Acrysol K140 at different concentrations of 0.5, 1, 3, 5%v/v. 
These micellar dispersions were then dried with the help of a spray 
dryer and solid particles were obtained. The fenofibrate 
microparticles were then filled in hard capsules and showed higher 
dissolution profile. The obtained MEM were further analysed for 
DSC and FTIR spectra. It was found that the use of Acrysol K140 as 
surfactant enhanced the solubility of fenofibrate up to 644 mg 
fenofibrate/1g surfactant. No chemical interactions between 
fenofibrate and Acrysol K140 were observed by DSC diagram and 
FTIR spectra [73]. 
CONCLUSION 
The delivery of hydrophobic drug to the targeting site is a 
challenging task for the researchers because of its limited solubility. 
Here, the focus is given for the hydrophobic drug that needs to be 
delivered topically. Micelles provide the rapid disintegration of the 
drug at the targeted site. Micellar microparticles improve the 
solubility and dissolution of the poorly soluble drugs and provide 
drug delivery to a targeted site whereby release of the drug is 
sustained. Such advantages of micellar microparticles provide the 
big scope in future for the delivery of hydrophobic drug topically 
with more efficacy and less production cost. 
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